Patients who have not had resection of recurrent PD must have measureable disease. 6. At least 56 of the approximately 76 patients treated must have measureable disease, defined as at least one, contrast-enhancing lesion measuring at least 1 cm in 2 planes (axial, coronal, or sagittal). 7. No evidence of hemorrhage on the baseline MRI or CT scan other than those that are ≤ Grade 1 and either post-operative or stable on at least 2 consecutive scans. 8. Recovery from prior therapy toxicity, defined as resolution of all treatment related AEs to ≤ Grade 1 or pre-treatment baseline (except alopecia and lymphopenia). DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 15 of 63 9. At least 12 weeks from prior radiotherapy to the start of SL-701 unless there is new enhancement outside of the radiation field or unequivocal histopathologic evidence of recurrent tumor subsequent to radiotherapy. 10. No chemotherapy or investigation agent for at least 3 weeks prior to the start of SL-701. 11. Human leukocyte antigen (HLA)-A2 positive. 12. A tumor tissue sample is provided for immunohistochemical analysis of relevant antigens, immune markers and potential prognostic factors. Preferably a paraffin block or 10-12 unstained slides will be submitted prior to study entry. Patients for whom tumor samples are unavailable or inadequate are permitted to participate in the study; however, the absence of available/adequate tumor specimen must be documented. 13. Karnofsky performance status (KPS) score ≥ 70% . 14. Adequate organ function, including the following:  Absolute neutrophil count (ANC) ≥ 1000/µL, platelets ≥ 100,0 00/µL  Serum creatinine ≤ 1.5 x the upper limit of normal (ULN)  Bilirubin ≤ 1.5 x ULN  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN 15. Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the start of SL-701 treatment. 16. Female patients of childbearing potential and sexually active male patients must agree to use an acceptable form of contraception for heterosexual activity (ie, or al contraceptives, double-barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for > 40 days before Screening, during the study, and for 60 days after the last dose of study drug. Men should not donate semen during the study and for 60 days after the last dose of study drug. 17. Female patients without childbearing potential (spontaneous amenorrhea for > 12 months or surgically sterilized by tubal ligation, hysterectomy, or bilateral oophorectomy > 6 months before Screening) are eligible for inclusion without contraceptive use restriction. 18.